help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dweik, R. A.
Right arrow Articles by Erzurum, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dweik, R. A.
Right arrow Articles by Erzurum, S. C.

Am. J. Respir. Cell Mol. Biol., Volume 24, Number 4, April, 2001 414-418

High Levels of Exhaled Nitric Oxide (NO) and NO Synthase III Expression in Lesional Smooth Muscle in Lymphangioleiomyomatosis

Raed A. Dweik, Daniel Laskowski, Metin Özkan, Carol Farver, and Serpil C. Erzurum

Departments of Pulmonary and Critical Care Medicine, Pathology, and Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio

Smooth-muscle proliferation is the hallmark of lymphangioleiomyomatosis (LAM). Although little is known about the pathogenesis of LAM, nitric oxide (NO) is a key regulator of smooth-muscle proliferation. NO is linked to the pathogenesis of other lung diseases such as asthma, in part by the finding of higher-than-normal levels of exhaled NO. If NO were involved in the abnormal smooth-muscle proliferation in LAM, we reasoned that exhaled NO from individuals with LAM would also differ from that of healthy control subjects. To evaluate this hypothesis, we studied exhaled NO in individuals with LAM in comparison with healthy and asthmatic women using a chemiluminescent NO analyzer. Women with LAM had higher exhaled NO than did healthy women but lower than asthmatic women (NO [parts per billion] median (25 to 75%): LAM 8 [7 to 15] [n = 28], control 6 [5 to 8] [n = 21], asthma 14 [8 to 25] [n = 22]; Kruskal-Wallis P < 0.001). Immunohistochemical studies on formalin-fixed, paraffin-embedded sections of surgical and autopsy material from lungs of individuals with LAM showed diffuse NO synthase III (NOSIII) expression in the lesional smooth muscle of LAM similar to that in the vascular endothelium. NOSIII expression was limited to the vascular endothelium and bronchial smooth muscle in healthy control lungs. The increased NO and the presence of NOSIII expression in lesional smooth muscle warrants further study into the potential role for NO in the pathogenesis of LAM.

Abbreviations: diffusion capacity, DLCO; forced expiratory volume in 1 s, FEV1; forced vital capacity, FVC; lymphangioleiomyomatosis, LAM; nitric oxide, NO; NO synthase, NOS; neuronal NOS, NOSI; inducible NOS, NOSII; endothelial NOS, NOSIII; parts per billion, ppb; standard error of the mean, SEM.




This article has been cited by other articles:


Home page
 Am. J. Respir. Cell Mol. Bio.Home page
L. Kobzik
Translating NO Biology into Clinical Advances: Still Searching for the Right Dictionary?
Am. J. Respir. Cell Mol. Biol., July 1, 2009; 41(1): 9 - 13.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Ghosh, A. J. Janocha, M. A. Aronica, S. Swaidani, S. A. A. Comhair, W. Xu, L. Zheng, S. Kaveti, M. Kinter, S. L. Hazen, et al.
Nitrotyrosine Proteome Survey in Asthma Identifies Oxidative Mechanism of Catalase Inactivation
J. Immunol., May 1, 2006; 176(9): 5587 - 5597.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
B. D. Hoit, N. D. Dalton, S. C. Erzurum, D. Laskowski, K. P. Strohl, and C. M. Beall
Nitric oxide and cardiopulmonary hemodynamics in Tibetan highlanders
J Appl Physiol, November 1, 2005; 99(5): 1796 - 1801.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
S. C. Land and C. Rae
iNOS initiates and sustains metabolic arrest in hypoxic lung adenocarcinoma cells: mechanism of cell survival in solid tumor core
Am J Physiol Cell Physiol, October 1, 2005; 289(4): C918 - C933.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. A. Masri, S. A. A. Comhair, T. Koeck, W. Xu, A. Janocha, S. Ghosh, R. A. Dweik, J. Golish, M. Kinter, D. J. Stuehr, et al.
Abnormalities in Nitric Oxide and Its Derivatives in Lung Cancer
Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 597 - 605.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005
Am. J. Respir. Crit. Care Med., April 15, 2005; 171(8): 912 - 930.
[Full Text] [PDF]

Home page
 ThoraxHome page
R A Dweik
Nitric oxide, hypoxia, and superoxide: the good, the bad, and the ugly!
Thorax, April 1, 2005; 60(4): 265 - 267.
[Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
S. B. Khatri, J. Hammel, M. S. Kavuru, S. C. Erzurum, and R. A. Dweik
Temporal association of nitric oxide levels and airflow in asthma after whole lung allergen challenge
J Appl Physiol, July 1, 2003; 95(1): 436 - 440.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
R. F. Machado, J. K. Stoller, D. Laskowski, S. Zheng, J. A. Lupica, R. A. Dweik, and S. C. Erzurum
Low levels of nitric oxide and carbon monoxide in alpha 1-antitrypsin deficiency
J Appl Physiol, December 1, 2002; 93(6): 2038 - 2043.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. B. KHATRI, M. OZKAN, K. MCCARTHY, D. LASKOWSKI, J. HAMMEL, R. A. DWEIK, and S. C. ERZURUM
Alterations in Exhaled Gas Profile during Allergen-induced Asthmatic Response
Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1844 - 1848.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 2001 American Thoracic Society. 		  Tobacco